Auxilium Pharmaceuticals (AUXL) 36.47 $AUXL
Global Male Hypogonadism Pipeline Review, H1 2015 - 16 Companies & 12 Drug Profiles
M2 - Mon Jun 08, 9:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cw4ztk/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Clarus Therapeutics, Inc. - Diurnal Ltd - EndoCeutics, Inc. - Ferring International Center S.A. - Forendo Pharma Oy - Lipocine Inc. - M et P Pharma AG - Merck & Co., Inc. - Monosol Rx, LLC - Novartis AG - Pantarhei Bioscience BV - Repros Therapeutics Inc. - SoluBest Ltd. Drug Profiles - BGS-649 - corifollitropin alfa - enclomiphene - fispemifene - follitropin alfa - Kisspeptin-10 - Libidua - LPCN-1111 - T-2 - Testavan - testosterone enanthate - testosterone next generation - testosterone undecanoate For more information visit http://www.researchandmarkets.com/research/cw...pogonadism
MRK: 56.81 (-0.37), AUXL: 36.47 (-0.06), LPCN: 8.16 (-0.94), ATRS: 1.05 (-0.04), NVS: 78.94 (-1.57)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 16.48 (-1.52), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 73.95 (-0.48), ABBV: 61.00 (+0.25), CBRX: 7.36 (+0.45), ATRS: 1.05 (-0.04)
Shares of AUXL Up 80.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 30, 11:07AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 7 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Uptrend Call Working As Auxilium Pharmaceuticals Stock Rises 80.6% (AUXL)
Comtex SmarTrend(R) - Mon Mar 23, 9:46AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 7 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Male Hypogonadism Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 9:32AM CDT
The report "Male Hypogonadism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Male hypogonadism is the inability of the testicles to produce testosterone, sperm or both. The symptoms of male hypogonadism includes weakness, muscle and joint aches, increased fat or obesity, enlarged, swollen or tender breasts, reduced facial, body and pubic hair, decreased bone density, bone fractures or osteoporosis, loss of height, sleep apnea, night sweats or hot flushes and fatigue. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/male-hypogon...eport.html .
MRK: 56.81 (-0.37), AUXL: 36.47 (-0.06), LPCN: 8.16 (-0.94), ATRS: 1.05 (-0.04), NVS: 78.94 (-1.57)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.93 (-6.47), ACET: 22.52 (-0.15), ABT: 38.40 (-0.47), AUXL: 36.47 (-0.06), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), AMRI: 14.59 (-0.28)
Auxilium Pharmaceuticals Up 80.6% Since SmarTrend Uptrend Call (AUXL)
Comtex SmarTrend(R) - Fri Feb 13, 9:09AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 5 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Auxilium Pharmaceuticals Has Returned 80.6% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Feb 05, 4:36PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 5 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding Convertible Senior Notes
PR Newswire Europe - Tue Feb 03, 7:01AM CST
Auxilium Pharmaceuticals, Inc. ("Auxilium"
today announced that it has delivered a notice to holders of its 1.50% convertible senior notes due 2018 (the "Notes" , pursuant to the indenture governing the Notes (as supplemented, the "Indenture" , notifying holders that, as a result of each of the merger (the "Merger" contemplated by the Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014, among Auxilium, Endo International plc ("Endo" , Endo U.S. Inc. and Avalon Merger Sub Inc., and the termination of trading of Auxilium common stock on NASDAQ, a "Fundamental Change" and a "Make-Whole Fundamental Change," each as defined in the Indenture, has occurred effective as of January 29, 2015.
AUXL: 36.47 (-0.06)
Endo Completes Acquisition Of Auxilium Pharmaceuticals
PR Newswire Europe - Thu Jan 29, 3:30PM CST
Endo International plc today announced it has completed the acquisition of Auxilium Pharmaceuticals, Inc. in a transaction valued at $2.6 billion when announced on October 9, 2014. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27, 2015, and the receipt of all required regulatory approvals.
ENDP: 16.48 (-1.52), ENL.TO: 21.18 (-1.61), AUXL: 36.47 (-0.06)
Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:10PM CST
Endo International has priced $1.2 billion aggregate principal amount of 6.00% senior notes due Feb 2025 at par with a face value of $1,000 on Jan 20.
ENDP: 16.48 (-1.52), AUXL: 36.47 (-0.06), ALXN: 135.61 (-2.63), AMAG: 21.04 (-0.82)
Global Male Hypogonadism Pipeline Review, H1 2015 - 16 Companies & 12 Drug Profiles
M2 - Mon Jun 08, 9:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cw4ztk/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Clarus Therapeutics, Inc. - Diurnal Ltd - EndoCeutics, Inc. - Ferring International Center S.A. - Forendo Pharma Oy - Lipocine Inc. - M et P Pharma AG - Merck & Co., Inc. - Monosol Rx, LLC - Novartis AG - Pantarhei Bioscience BV - Repros Therapeutics Inc. - SoluBest Ltd. Drug Profiles - BGS-649 - corifollitropin alfa - enclomiphene - fispemifene - follitropin alfa - Kisspeptin-10 - Libidua - LPCN-1111 - T-2 - Testavan - testosterone enanthate - testosterone next generation - testosterone undecanoate For more information visit http://www.researchandmarkets.com/research/cw...pogonadism
MRK: 56.81 (-0.37), AUXL: 36.47 (-0.06), LPCN: 8.16 (-0.94), ATRS: 1.05 (-0.04), NVS: 78.94 (-1.57)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 16.48 (-1.52), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 73.95 (-0.48), ABBV: 61.00 (+0.25), CBRX: 7.36 (+0.45), ATRS: 1.05 (-0.04)
Shares of AUXL Up 80.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 30, 11:07AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 7 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Uptrend Call Working As Auxilium Pharmaceuticals Stock Rises 80.6% (AUXL)
Comtex SmarTrend(R) - Mon Mar 23, 9:46AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 7 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Male Hypogonadism Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 9:32AM CDT
The report "Male Hypogonadism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Male hypogonadism is the inability of the testicles to produce testosterone, sperm or both. The symptoms of male hypogonadism includes weakness, muscle and joint aches, increased fat or obesity, enlarged, swollen or tender breasts, reduced facial, body and pubic hair, decreased bone density, bone fractures or osteoporosis, loss of height, sleep apnea, night sweats or hot flushes and fatigue. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/male-hypogon...eport.html .
MRK: 56.81 (-0.37), AUXL: 36.47 (-0.06), LPCN: 8.16 (-0.94), ATRS: 1.05 (-0.04), NVS: 78.94 (-1.57)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.93 (-6.47), ACET: 22.52 (-0.15), ABT: 38.40 (-0.47), AUXL: 36.47 (-0.06), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), AMRI: 14.59 (-0.28)
Auxilium Pharmaceuticals Up 80.6% Since SmarTrend Uptrend Call (AUXL)
Comtex SmarTrend(R) - Fri Feb 13, 9:09AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 5 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Auxilium Pharmaceuticals Has Returned 80.6% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Feb 05, 4:36PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 5 months, Auxilium Pharmaceuticals has returned 80.59% as of today's recent price of $36.47.
AUXL: 36.47 (-0.06)
Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding Convertible Senior Notes
PR Newswire Europe - Tue Feb 03, 7:01AM CST
Auxilium Pharmaceuticals, Inc. ("Auxilium"
today announced that it has delivered a notice to holders of its 1.50% convertible senior notes due 2018 (the "Notes" , pursuant to the indenture governing the Notes (as supplemented, the "Indenture" , notifying holders that, as a result of each of the merger (the "Merger" contemplated by the Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014, among Auxilium, Endo International plc ("Endo" , Endo U.S. Inc. and Avalon Merger Sub Inc., and the termination of trading of Auxilium common stock on NASDAQ, a "Fundamental Change" and a "Make-Whole Fundamental Change," each as defined in the Indenture, has occurred effective as of January 29, 2015. AUXL: 36.47 (-0.06)
Endo Completes Acquisition Of Auxilium Pharmaceuticals
PR Newswire Europe - Thu Jan 29, 3:30PM CST
Endo International plc today announced it has completed the acquisition of Auxilium Pharmaceuticals, Inc. in a transaction valued at $2.6 billion when announced on October 9, 2014. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27, 2015, and the receipt of all required regulatory approvals.
ENDP: 16.48 (-1.52), ENL.TO: 21.18 (-1.61), AUXL: 36.47 (-0.06)
Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:10PM CST
Endo International has priced $1.2 billion aggregate principal amount of 6.00% senior notes due Feb 2025 at par with a face value of $1,000 on Jan 20.
ENDP: 16.48 (-1.52), AUXL: 36.47 (-0.06), ALXN: 135.61 (-2.63), AMAG: 21.04 (-0.82)
